1. Introduction {#s0005}
===============

The coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality to date, with the number of new cases and deaths continue to rise at an alarming rate \[[@bb0005]\]. Although most cases of COVID-19 are asymptomatic or mild in severity, a minority of patients experience more severe symptoms of COVID-19 along with its complications, such as acute respiratory distress syndrome (ARDS), coagulopathy, multiple organ failure (MOF), and death. A number of comorbidities have been associated with an increased risk of severity and mortality in COVID-19 patients, including hypertension, diabetes, cerebrovascular disease, chronic kidney disease, and chronic obstructive pulmonary disease \[[@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030]\]. Individuals with preexisting cardiovascular diseases have been shown to have poor outcomes with COVID 19 \[[@bb0035],[@bb0040]\]. Study from Chinese center of disease control on 72,314 cases reported a case fatality rate of 10.5% for patients with preexisting cardiovascular disease, but no specific data on mortality on heart failure \[[@bb0045]\]. Due to looming possibility of poor drug compliance and other complications related to disruption in medical services, the number of patients with new or decompensated heart failure may increase \[[@bb0050]\].

Currently, the plausible mechanisms for SARS-CoV-2 (severe acute respiratory syndrome 2) to infect human cells include binding to the angiotensin-converting enzyme 2 (ACE2) receptor and inducing hyperinflammation or cytokine storm. A high expression of ACE2 receptor is commonly found in patients with heart failure \[[@bb0035],[@bb0040]\]. In this systematic review and meta-analysis, we wanted to investigate the association between heart failure with poor outcome in patients with COVID-19.

2. Methods {#s0010}
==========

2.1. Search and selection criteria {#s0015}
----------------------------------

We performed a systematic search of the literature on PubMed, EuropePMC, SCOPUS, Cochrane Central Database, and medRxiv for preprint studies with the search terms, "Heart Failure" and "COVID-19". After the removal of duplicates, the abstracts were screened by two independent authors (EY and RP). Irrelevant articles were excluded. The inclusion criteria for this study were studies that studied patients with preexisting HF comorbidity with COVID-19 infection. The outcome of interest was mortality and poor prognosis (defined by incidence of severe COVID-19 infection, admission to ICU, and use of ventilator) in patients with preexisting heart failure with coronavirus disease. This systematic search conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

2.2. Data extraction {#s0020}
--------------------

Data extraction was carried out by EY, RP, MAL, and IH using a standardized form containing the following details: author name, year of publication, study design, and sample size.

2.3. Statistical analysis {#s0025}
-------------------------

This meta-analysis was conducted using Review Manager (RevMan) v5.3 (Cochrane Collaboration) software. Hazard ratio (HR) and odds ratio (OR) with 95% confidence interval (CI) were used as pooled measures for dichotomous data. Heterogeneity was assessed using Inconsistency Index (I^2^) ranging from 0 to 100%. Statistically significant heterogeneity was defined as an I^2^ value above 50% or *p* \< 0.05. The Mantel--Haenszel method was used to determine OR, and the generic inverse variance method was used to determine HR. Random effects models were implemented for analyses with significant heterogeneity. Sensitivity analyses were done to test statistical robustness of pooled results, to see whether there is significant change in pooled results by exclusion of studies, and to single out studies with high heterogeneity. Meta-analysis of prevalence was done by pooling of events of HF per total patients using the meta-analysis of proportion. Small-study effects and the risk of publication bias were assessed qualitatively using funnel plot analysis and quantitatively using regression-based Egger\'s test.

3. Results {#s0030}
==========

We extracted 204 potential articles from our search, and 22 duplicates were removed. After the titles and abstracts of the remaining 182 articles were screened we obtained 92 potentially relevant articles. We excluded 74 studies due to the following reasons: four studies were systematic reviews, two studies were meta-analyses, three articles were literature reviews, and 65 articles did not report on the outcome of interest. Finally, we included the remaining 18 studies in our qualitative synthesis and meta-analysis. There were 21,640 patients from 18 studies. The majority of study subjects are males ranging from 54.7% to 85%, with only two studies reported male subjects being minorities, (45.1% on study by Caraballo C et al. and 44.3% on study by Ji W et al.) ([Table 1](#t0005){ref-type="table"} , [Fig. 1](#f0005){ref-type="fig"} ).Table 1Studies included in Meta AnalysisTable 1Author, yearStudy designOutcome of interestSamplesOutcome vs no outcomeMaleOverall ageHFOutcome/total HF vs No HFHF outcome vs no outcomeNew Onset HFHRInciardi RM 2020Observational, prospective cohortMortality5319 vs 3485%68 ± 1221/5312/21 vs 7/3212/19 vs 9/26N/AN/AChen T 2020RetrospectiveMortality274113 vs 16162%62.0 (44.0--70.0)1/2741/1 vs 112/2731/113 vs 0/16141/83 vs 3/94N/APetrilli 2020RetrospectiveCritical illness2729990 vs 173961.3%63 (51--74)349/2729189/349 vs 801/2380189/990 vs 160/1739N/AHR mortality 1.77 (1.43 to 2.20)RetrospectiveHospitalization2729N/A61.3%63--51-74N/AN/AN/AN/A4.56 \[2.59, 8.04\]Yin W 2020RetrospectiveMortality11252 vs 6068.7%66.00(56.00--76.00)2(1.8%)2/2 vs 50/1102/52 vs 0/60N/AN/AZhou FRetrospectiveMortality19154 vs 13762%56·0 (46·0--67·0)44 (23%)N/AN/A28/54 vs 16/137N/ABaker KF 2020Retrospectivemortality31681 vs 23554.775 (60--83)1120/45 vs 61/27120/81 vs 23/210N/AOR 2.67 \[1.36--5.19\], *p* = .004Cummings MJRetrospectiveMortality25786/257 (33%)66%62 (51--72)49/257 (CVD)N/AN/AN/AUnivariate 0.62 (0.33--1.17)\
Multivariate 0.69 (0.34--1.42)Caraballo CRetrospectiveMortality206 COVID positive34 vs 17245.1%78 (65--87)36/2063/36 vs 31/1363/34 vs 33/172N/A???Heng GERetrospectiveMortality5112 vs 3972.5%70 (58--79)4/514/4 vs 35/470/20 vs 4/31N/AN/ASeverity5120 vs 3172.5%70 (58--79)4/511/20 vs 3/31N/AN/AGaribaldi BT 2020RetrospectiveMortality747113 vs 63453.2%63 (49, 75)127 (15.3%)33/127 vs 80/63433/113 vs 67/634N/AN/AEbinger JERetrospectiveSeverity (ICU care)44277 vs 36558%52.7 ± 19.749 (11%) (prior MI or HF)18/49 vs 59/39318/ 77 vs 31/365N/AUnivariate 1.72 (0.96,3.09) 0.07\
Multivariate 0.56 (0.27,1.18) 0.13Liao XRetrospectiveMortality/ventilator support8110 vs 7163%50.0 (39.0--65.0)4 (4.9%1/4 vs 9/771/10 vs 3/71N/AN/AJi WRetrospectiveSeverity5172293 vs 487944.3%42 (18--100)217 (4.2)44/217 vs 249/495544/293 vs 173/4879N/A(Odds ratio range 1.562--1.730)Paranjpe IRetrospectiveMortality1078310 vs 76858.1%Dead 75 (64--85)\
Alive 59 (45--72)117/107864/117 vs 246/96164/310 vs 53/768N/AN/ARossi PGRetrospectiveHospitalization2653217 vs61.9%51--8196/1075N/AN/AN/AHR 1.6, 95% CI 1.2 to 2.1Mortality1292217 vs 1075800 (61.9%)51--81139/129243/137 vs 174/251643/217 vs 96/1075N/AHR 2.3, 95% CI 1.6 to 3.2Yanover CRetrospectiveCritical care/death4353173 vs 418056.5%35 \[22--54\]30/435311/30 vs 162/432311/173 vs 19/4180N/AN/AArgenziano MGRetrospectiveICU Care (SEVERE COVID)850236 vs 61459.6%63.0 (50.0--75.0)91/850N/A24/236 vs 67/61418/236 vs 6/614N/AReilev MRetrospectiveHospitalizationN/AN/AN/AN/AN/AN/AN/AN/A2.2 (1.7--2.9)\
(age adjusted)RetrospectiveMortality2090524 vs 156657%82 (75--89)218/209098/204 vs 426/188698/524 vs 120/2090N/A1.7 (1.3--2.2)\
(age adjusted)Fig. 1PRISMA diagram.Fig. 1

3.1. Risk of hospitalization in patients with preexisting heart failure {#s0035}
-----------------------------------------------------------------------

Three studies reported a statistically significant difference in the risk of hospitalization in COVID19 patients with preexisting heart failure. The pooled HR was 2.37 \[1.48, 3.79; *p* \< 0.001\], with moderately high heterogeneity between studies \[I^2^, 82%; *p* \< 0.001\]. Sensitivity analysis was performed, excluding the study by Petrilli et al., yielded HR 1.88 \[1.36, 2.62; *p* \< 0.001\] with moderate heterogeneity between studies \[I^2^, 65%; *p* = 0.09\] ([Fig. 2](#f0010){ref-type="fig"} ).Fig. 2Meta analysis, risk of hospitalization in patients with pre-existing heart failure.Fig. 2

3.2. Heart failure and poor outcome {#s0040}
-----------------------------------

Statistically significant differences in composite poor outcomes were reported in 15 studies. HF was associated with a poor outcome demonstrated by an OR of 2.86 \[2.07; 3.95; *p* \< 0.001\] with high heterogeneity between studies \[I^2^, 80%; p \< 0.001\]. Sensitivity analyses were performed. Exclusion of the studies by Argenziano et al., Caraballo et al., Ji W et al., Paranjpe et al., Reilev et al., and Yanover et al. yielded an OR of 2.56 \[2.17, 3.03, *p* \< 0.001\] with low heterogeneity between studies \[I^2^, 0%; *p* = 0.55\] ([Fig. 3](#f0015){ref-type="fig"} ).Fig. 3Meta analysis, heart failure and poor outcome.Fig. 3

3.3. Pooled HR of mortality in patients with coronavirus disease 2019 with preexisting heart failure {#s0045}
----------------------------------------------------------------------------------------------------

Seven studies reported a statistically significant difference in mortality between patients with COVID-19 with and without preexisting HF. The pooled HR was 1.70 \[1.44, 2.02; *p* \< 0.001\] with moderate heterogeneity between studies \[I^2^, 59%; *p* = 0.02\]. Sensitivity analysis was performed, excluding the study by Cummings which yielded an HR of 1.70 \[1.57, 1.83; *p* \< 0.001\] with a low heterogeneity between studies \[I^2^, 9%; *p* = 0.36\] ([Fig. 4](#f0020){ref-type="fig"} ).Fig. 4Meta analysis, pooled HR of mortality in COVID19 patients with pre-existing heart failure.Fig. 4

3.4. Comparison of mortality in patients with coronavirus disease 2019 accompanied with preexisting heart failure and without heart failure {#s0050}
-------------------------------------------------------------------------------------------------------------------------------------------

Fourteen studies reported a statistically significant difference in mortality between patients with COVID-19 accompanied with and without preexisting heart failure. Pooled events yielded an OR of 3.46 \[2.52, 4.75; *p* \< 0.001\] with moderately high heterogeneity between studies \[I^2^, 77%; *p* \< 0.001\]. Sensitivity analyses were performed, excluding the studies by Caraballo et al., Ji W et al., Rossi et al., and Yanover et al. which yielded OR of 2.77 \[2.40, 3.20; p \< 0.001\] with low heterogeneity between studies \[I^2^, 0%; *p* = 0.73\] ([Fig. 5](#f0025){ref-type="fig"} ).Fig. 5Meta analysis, mortality in COVID19 patients with pre-existing heart failure compared to nonheart failure patients.Fig. 5

3.5. Incidence of new-onset heart failure in patients with coronavirus disease 2019 {#s0055}
-----------------------------------------------------------------------------------

Three studies reported a statistically significant difference in incidence of new-onset HF in hospitalized patients with COVID-19. Pooled results yielded an OR of 11.67 \[6.96, 19.56; *p* \< 0.001\] with moderate heterogeneity between studies \[I^2^, 44%; p0.17\]. Sensitivity analysis was performed, excluding the study by Chen et al. which yielded an OR of 8.24 \[4.59, 14.78; *p* \< 0.001\] with low heterogeneity between studies \[I^2^, 0%; *p* \< 0.96\] ([Fig. 6](#f0030){ref-type="fig"} ).Fig. 6Meta analysis, incidence of new-onset heart failure in COVID19 patients.Fig. 6

3.6. Meta-analysis of prevalence {#s0060}
--------------------------------

Sixteen studies were available for meta-analysis to determine the pooled prevalence of heart failure among patients with COVID-19; the meta-analysis revealed a pooled prevalence of heart failure of 9% (7--12%) ([Fig. 7](#f0035){ref-type="fig"} ).Fig. 7Meta prevalence of heart failure patients in study population.Fig. 7

3.7. Publication bias {#s0065}
---------------------

Regression-based Egger\'s test showed no indication of small-study effects for Heart Failure and Poor Outcome (*p* = 0.852), Pooled HR of mortality in patients with coronavirus disease 2019 with preexisting heart failure (*p* = 0.640), and Comparison of mortality in patients with coronavirus disease 2019 accompanied with preexisting heart failure and without heart failure (*p* = 0.555). There was an indication of small-study effects for Risk of hospitalization in patients with preexisting heart failure (*p* = 0.035) and Incidence of new-onset heart failure (*p* \< 0.001). The number of included studies were \<10 for risk of hospitalization in patients with preexisting heart failure, Pooled HR of mortality in patients with coronavirus disease 2019 with preexisting heart failure, and incidence new onset heart failure, thus, the results were less reliable. Analysis using funnel plot generated asymmetrical result for Heart Failure and Poor Outcome ([Fig. 8](#f0040){ref-type="fig"}A), and Comparison of mortality in patients with coronavirus disease 2019 accompanied with preexisting heart failure and without heart failure ([Fig. 8](#f0040){ref-type="fig"}B), with [Fig. 8](#f0040){ref-type="fig"}A showing somewhat less asymmetry compared to [Fig. 8](#f0040){ref-type="fig"}B. Based on Cochrane collaboration recommendation we only performed funnel plot analysis in meta-analysis involving more than 10 studies.Fig. 8A. Funnel plot analysis, heart failure and poor outcome. B. Funnel plot analysis, comparison of mortality in patients with coronavirus disease 2019 accompanied with preexisting heart failure and without heart failure.Fig. 8

4. Discussion {#s0070}
=============

In this meta-analysis, we observed an association between HF and poor outcome in patients with COVID-19, a higher risk of death and hospitalization in those with preexisting HF, and higher mortality in those with preexisting HF compared to patients without HF.

As with other types of pneumonia, preexisting cardiovascular diseases, including HF, are risk factors for poor prognosis during and after the course of pneumonia \[[@bb0055]\]. The effect of an infective organism on the myocardium can cause non-ischemic cardiac injury. The systemic inflammatory response, which is particularly excessively elevated in COVID-19, can also result in kidney injury and impair sodium and water metabolism, which may precipitate the worsening of HF \[[@bb0060]\].

Recent studies on the role of ACE2 in COVID-19 infection have reported that ACE2 levels are 50% higher in male patients with HF \[[@bb0065], [@bb0070], [@bb0075]\]. This finding explains the higher risk of poor prognosis, hospitalization, and death in this population in the event of occurrence of COVID-19. In this meta-analysis, the majority of the studies had higher number of male patients than female patients.

In patients with coexisting HF and diabetes, who are in a pro-inflammatory state, the membrane-bound ACE2 protein can be cleaved by ADAM17, resulting in the release of ACE2 into the interstitium and blood circulation \[[@bb0080]\]. This inflammatory response, which occurs in COVID-19 as an elevated immune response \[[@bb0085],[@bb0090]\] might also explain the increase in mortality in patients with COVID-19 accompanied with HF. The excessive inflammatory response and oxidative stress in these patients predispose them to a more severe clinical course of COVID-19 \[[@bb0095]\]. This phenomenon is particularly significant in patients with preexisting HF since these patients suffer from decreased circulatory and physiological reserves. Older patients with HF commonly suffer from multiple comorbidities, deterioration in function of multiple organ systems, and functional decline \[[@bb0100],[@bb0105]\].

ACE2 is an enzyme involved in the RAAS pathway; however, it differs from ACE in not being capable of converting angiotensin I into angiotensin II. Furthermore, as opposed to the vasoconstrictor property of angiotensin type 1 receptors, ACE2 via the ACE-2 receptors cleaves angiotensin II into angiotensin 1--7, which has vasodilatory properties \[[@bb0110]\].

Based on these explanations, it is easy for us to conclude regarding the dangers of upregulation of ACE2 as in patients being treated with renin-angiotensin system blockers (RASB). One study has even proposed ceasing administration of RASB in patients with COVID-19 on these drugs \[[@bb0115]\]. However, this does not seem to be the case, and several other authors have questioned this hypothesis \[[@bb0120], [@bb0125], [@bb0130], [@bb0135]\]. The rationale for this rebuttal is based upon several in vitro studies, which revealed that upon entry into alveolar cells using membrane-bound ACE-2 receptors, SARS-CoV-2 downregulates the expression and causes internalization of ACE2 receptors. The result of this process is a decrease in angiotensin-II to angiotensin (1--7) conversion and an increase in the availability of angiotensin II to bind to the AT1 receptor. This induces cellular inflammation, oxidative stress, vasoconstriction, fibrosis, and aldosterone activation, which may eventually lead to lung injury \[[@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160]\]. The use of RASB may serve as a protective measure against lung injury by the inhibition of angiotensin II synthesis using ACEIs and blockade of AT1R by ARBs. This would result in a skew of the RAAS towards angiotensin (1--7) and its subsequent interaction with Mas-receptors, which may minimize the risk of lung injury \[[@bb0145],[@bb0165]\].

The result of this meta-analysis is similar to that of previous studies in which patients with preexisting heart HF demonstrated an elevated risk of poor outcome, hospitalization, and death \[31--49\] \[[@bb0170]\] \[[@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195], [@bb0200], [@bb0205]\] \[[@bb0210], [@bb0215], [@bb0220], [@bb0225], [@bb0230], [@bb0235], [@bb0240], [@bb0245], [@bb0250]\] \[[@bb0255],[@bb0260]\].

Compared to other diseases, based on our pooled results, patients with HF suffering from SARS-CoV-2 infection have a threefold increased risk of in-hospital mortality compared to patients with HF who develop influenza, OR 3.46 \[2.52, 4.75; *p* \< 0.001\] vs. OR 1.15 \[1.03, 1.30; *p* = 0.02\] and OR 1.66 \[1.44--1.91; *p* \< 0.001\] \[[@bb0265],[@bb0270]\]. However, when compared to patients infected with Middle East respiratory syndrome coronavirus (MERS-CoV), patients with preexisting HF who developed COVID-19 had a lower risk of mortality \[OR 3.46; 2.52, 4.75; *p* \< 0.001 vs OR, 12.981; 1.324, 127.313; *p* = 0.025\] \[[@bb0275]\].

Studies have shown a poorer prognosis in patients with HF who develop influenza \[[@bb0265],[@bb0270]\]. As a result of the decreased physiological reserve, influenza virus infection in patients with HF is associated with a severe course and significant hemodynamic compromise, which often requires cardiac support \[[@bb0280]\]. Influenza vaccination in these patients is associated with a reduced risk of all-cause and cardiovascular death, furthermore receiving \>1 influenza vaccine is associated with 18% reduction in both all-cause and cardiovascular death (all-cause death: 0.82; 95% CI,0.81--0.84; *p* \< 0.001; cardiovascular death: 0.82; 95% CI, 0.81--0.84; *p* \< 0.001), in the event of influenza infection, patients with heart failure may fail to cope with the increased metabolic demand which is caused by the infection itself, as a result, decompensation or exacerbation in heart failure symptoms may occur \[[@bb0285]\]. Patients with HF are currently classified as a high-priority group to be vaccinated with the influenza vaccine \[[@bb0290]\]. Based on these findings, once an effective vaccine for SARS-CoV-2 infection becomes available, patients with HF should be prioritized to be vaccinated even in case of COVID-19.

We observed some limitations of this meta-analysis, such as the use of preprint studies included in this meta-analysis. Additionally, several studies have been conducted in the same cities/regions, posing a risk of subject overlap. Data regarding the difference between new-onset and worsening of HF in patients in the studies was rarely available. Data regarding staging of HF was also rarely found. Additionally, in patients with HF suffering from a severe course of COVID-19 infection, data regarding the use of vasopressors and inotropic agents as well as the incidence of cardiogenic shock was lacking.

5. Conclusion {#s0075}
=============

In conclusion, patients with HF are at increased risk for poor outcomes such as hospitalization, and death from COVID-19. A significant difference in mortality between patients with and without HF was observed, those with HF showing higher mortality rates. These findings probably stem from the reduced physiological reserves in patients with HF. Mortality of patients with HF accompanied with SARS-CoV-2 infection is higher than that of patients with influenza, but lower than that of patients with MERS-CoV. Thus, if SARS-CoV-2 vaccine becomes available, patients with HF should be prioritized to be vaccinated.
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